130 related articles for article (PubMed ID: 6834584)
1. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer.
Mughal AW; Hortobagyi GN; Fritsche HA; Buzdar AU; Yap HY; Blumenschein GR
JAMA; 1983 Apr; 249(14):1881-6. PubMed ID: 6834584
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
Loprinzi CL; Tormey DC; Rasmussen P; Falkson G; Davis TE; Falkson HC; Chang AY
J Clin Oncol; 1986 Jan; 4(1):46-56. PubMed ID: 3510282
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of serial carcinoembryonic antigen (CEA) determinations in monitoring chemotherapy.
Young VL; Kashmiri R; Hazen ZR; Meeker WR
South Med J; 1976 Oct; 69(10):1274-6. PubMed ID: 982100
[TBL] [Abstract][Full Text] [Related]
4. [Determination of the carcinoembryonic antigen (CEA) for predicting the success of therapy in metastatic breast cancer].
Krieger G; Wander HE; Prangen M; Bandlow G; Beyer JH; Nagel GA
Dtsch Med Wochenschr; 1983 Apr; 108(16):610-4. PubMed ID: 6839982
[TBL] [Abstract][Full Text] [Related]
5. Role of plasma carcinoembryonic antigen in evaluating patients with breast cancer treated with adjuvant chemotherapy.
Falkson HC; van der Watt JJ; Portugal MA; Schoeman HS; Falkson G
Cancer Treat Rep; 1979 Aug; 63(8):1303-9. PubMed ID: 476707
[TBL] [Abstract][Full Text] [Related]
6. [Carcinoembryonic antigens (CEA) in patients with metastatic breast cancer under endocrine and therapeutic treatment (author's transl)].
Pompecki R; Schröder G; Garbrecht M; Frahm H
Dtsch Med Wochenschr; 1978 Apr; 103(14):620-2. PubMed ID: 639696
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen.
Silva JS; Leight GS; Haagensen DE; Tallos PB; Cox EB; Dilley WG; Wells SA
Cancer; 1982 Mar; 49(6):1236-42. PubMed ID: 6174201
[TBL] [Abstract][Full Text] [Related]
8. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer].
Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108
[TBL] [Abstract][Full Text] [Related]
9. Carcinoembryonic antigen in patients with breast cancer: an adjunctive tool to monitor response and therapy.
Falkson HC; Van Der Watt JJ; Portugal MA; Pitout MJ; Falkson G
Cancer; 1978 Sep; 42(3):1308-13. PubMed ID: 698917
[TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
11. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
Cancer; 1979 Apr; 43(4):1225-33. PubMed ID: 445325
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen as a marker in patients with breast cancer receiving postsurgical adjuvant chemotherapy.
Falkson HC; Falkson G; Portugal MA; van der Watt JJ; Schoeman HS
Cancer; 1982 May; 49(9):1859-65. PubMed ID: 7074585
[TBL] [Abstract][Full Text] [Related]
13. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in metastatic breast cancer treated with combination chemotherapy.
Swenerton KD; Legha SS; Smith T; Hortobagyi GN; Gehan EA; Yap HY; Gutterman JU; Blumenschein GR
Cancer Res; 1979 May; 39(5):1552-62. PubMed ID: 427797
[TBL] [Abstract][Full Text] [Related]
15. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.
Hortobagyi GN; Yap HY; Blumenschein GR; Gutterman JU; Buzdar AU; Tashima CK; Hersh EM
Cancer Treat Rep; 1978 Nov; 62(11):1685-92. PubMed ID: 728894
[TBL] [Abstract][Full Text] [Related]
16. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer: a predictor and monitor of response and relapse.
Lokich JJ; Zamcheck N; Lowenstein MW
Ann Intern Med; 1978 Dec; 89(6):902-6. PubMed ID: 717986
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
[TBL] [Abstract][Full Text] [Related]
18. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
19. Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: multicenter trial.
Ahn MJ; Noh YH; Lee YS; Lee YY; Choi IY; Kim IS; Joh EK; Shin DB; Kim SY; Cho KS; Kim HC; Kim HS; Suh CW; Kim SH; Lee JA; Park YS
J Korean Med Sci; 2001 Apr; 16(2):175-82. PubMed ID: 11306743
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
